JP2024516174A - 新規エルゴリン及び気分障害を処置する方法 - Google Patents

新規エルゴリン及び気分障害を処置する方法 Download PDF

Info

Publication number
JP2024516174A
JP2024516174A JP2023564585A JP2023564585A JP2024516174A JP 2024516174 A JP2024516174 A JP 2024516174A JP 2023564585 A JP2023564585 A JP 2023564585A JP 2023564585 A JP2023564585 A JP 2023564585A JP 2024516174 A JP2024516174 A JP 2024516174A
Authority
JP
Japan
Prior art keywords
disorder
alkyl
group
optionally substituted
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023564585A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022226408A5 (https=
JP2024516174A5 (https=
Inventor
アンドリュー・キャリー・クリューゲル
Original Assignee
ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド filed Critical ギルガメッシュ・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2024516174A publication Critical patent/JP2024516174A/ja
Publication of JPWO2022226408A5 publication Critical patent/JPWO2022226408A5/ja
Publication of JP2024516174A5 publication Critical patent/JP2024516174A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • C07D457/08—Lysergic acid amides in which the amide nitrogen is a member of a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2023564585A 2021-04-23 2022-04-25 新規エルゴリン及び気分障害を処置する方法 Pending JP2024516174A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163179053P 2021-04-23 2021-04-23
US63/179,053 2021-04-23
US202263308376P 2022-02-09 2022-02-09
US63/308,376 2022-02-09
PCT/US2022/026186 WO2022226408A1 (en) 2021-04-23 2022-04-25 Novel ergolines and methods of treating mood disorders

Publications (3)

Publication Number Publication Date
JP2024516174A true JP2024516174A (ja) 2024-04-12
JPWO2022226408A5 JPWO2022226408A5 (https=) 2025-05-09
JP2024516174A5 JP2024516174A5 (https=) 2025-05-09

Family

ID=81648213

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564585A Pending JP2024516174A (ja) 2021-04-23 2022-04-25 新規エルゴリン及び気分障害を処置する方法

Country Status (10)

Country Link
US (1) US20240368151A1 (https=)
EP (1) EP4326718A1 (https=)
JP (1) JP2024516174A (https=)
KR (1) KR20240019091A (https=)
AU (1) AU2022262659A1 (https=)
BR (1) BR112023021970A2 (https=)
CA (1) CA3223210A1 (https=)
IL (1) IL307880A (https=)
MX (1) MX2023012447A (https=)
WO (1) WO2022226408A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230116703A1 (en) * 2021-04-23 2023-04-13 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
CN117355302A (zh) 2021-04-30 2024-01-05 思维医学股份有限公司 Lsd盐晶体形式
JP2024529727A (ja) 2021-08-19 2024-08-08 マインド メディシン， インコーポレイテッド 治療適用のためのｄ－リゼルグ酸ジエチルアミドの凍結乾燥された口腔内崩壊錠製剤
JP2025525375A (ja) * 2022-06-20 2025-08-05 マインド メディシン， インコーポレイテッド 修飾ｌｓｄ様作用を有するリゼルグ酸誘導体
EP4630418B1 (en) * 2022-12-31 2026-03-18 Ceruvia Lifesciences LLC Salts of 2-bromolysergic acid diethylamide
EP4704846A2 (en) * 2023-05-04 2026-03-11 Gilgamesh Pharmaceuticals, Inc. Novel ergolines and methods of treating mood disorders
WO2025194238A1 (en) * 2024-03-22 2025-09-25 Blife Therapeutics Inc. 2-bromo-lsd salts and polymorphs
WO2025235800A1 (en) 2024-05-08 2025-11-13 Cy Biopharma Ag Ergoline derivatives and uses thereof
WO2025235784A2 (en) * 2024-05-08 2025-11-13 Cy Biopharma Ag Ergoline derivatives and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2438259A (en) * 1948-03-23 D-lysergic acid diethyl amide
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
WO2021076572A1 (en) * 2019-10-14 2021-04-22 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
EP4178956A2 (en) * 2020-07-07 2023-05-17 COMPASS Pathfinder Limited Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2438259A (en) * 1948-03-23 D-lysergic acid diethyl amide
WO2020181194A1 (en) * 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
WO2021076572A1 (en) * 2019-10-14 2021-04-22 The Regents Of The University Of California Ergoline-like compounds for promoting neural plasticity

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
J. MED. CHEM., vol. 28, JPN6026003458, 1985, pages 1252 - 1255, ISSN: 0005787944 *
J. MED. CHEM., vol. 38, JPN6026003456, 1995, pages 958 - 966, ISSN: 0005787942 *
J. MED. CHEM., vol. 45, JPN6026003457, 2002, pages 4344 - 4349, ISSN: 0005787943 *
ORGANIC SQUARE, JPN6026003459, 2010, pages 2 - 3, ISSN: 0005787945 *

Also Published As

Publication number Publication date
IL307880A (en) 2023-12-01
AU2022262659A1 (en) 2023-10-19
US20240368151A1 (en) 2024-11-07
EP4326718A1 (en) 2024-02-28
WO2022226408A1 (en) 2022-10-27
CA3223210A1 (en) 2022-12-27
KR20240019091A (ko) 2024-02-14
BR112023021970A2 (pt) 2023-12-26
MX2023012447A (es) 2023-10-31

Similar Documents

Publication Publication Date Title
JP2024516174A (ja) 新規エルゴリン及び気分障害を処置する方法
JP2026508463A (ja) 新規エルゴリン及び気分障害を処置する方法
TWI659951B (zh) 吡咯啶ｇｐｒ４０調節劑
EP3675848B1 (en) Spirocycle compounds and methods of making and using same
KR20230026405A (ko) Nav1.8 억제제로서의 5-옥소피롤리딘-3-카르복스아미드
US20240166618A1 (en) Phenalkylamines and methods of making and using the same
CN109496213B (zh) 螺环化合物及其制备和使用方法
CA2891574A1 (en) Dihydropyrazole gpr40 modulators
JP6786566B2 (ja) ヘテロアリール化合物及びその使用方法
US12428373B2 (en) Dopamine D2 receptor ligands
EP4704846A2 (en) Novel ergolines and methods of treating mood disorders
WO2014021273A1 (ja) モルヒナン誘導体
CN119390705A (zh) 作为m4激动剂的5-氧杂-2-氮杂螺[3.4]辛烷衍生物
EP4327814A2 (en) Morpholinyl, piperazinyl, oxazepanyl and diazepanyl o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
CN120787225A (zh) 新型麦角林类和治疗心境障碍的方法
CN117677618A (zh) 新颖的麦角灵类和治疗心境障碍的方法
JP2023504862A (ja) ブルトン型チロシンキナーゼ阻害剤としてのイミダゾールカルボキサミド誘導体
US20250109143A1 (en) Klf2 inducing deuterated compounds and uses thereof
KR20260053282A (ko) 정신 질환의 치료를 위한 피롤로피리딘 화합물
WO2024059090A1 (en) Phenalkylamines and methods of making and using the same
AU2024341987A1 (en) Novel phenalkylamines and their use in the treatment of psychiatric disorders
WO2022268154A1 (zh) 新型抗乙肝化合物
HK40004417A (en) Spirocycle compounds and methods of making and using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203